PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization ...

The new investment will support both organic and inorganic expansion, including growth in sterile fill-finish injectables, ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and ...

More recently, PCI acquired a 100% stake in Ajinomoto’s fill-finish contracting arm Ajinomoto Althea. The deal, for which ...

A Philadelphia-based pharmaceutical services company has just received a massive investment from two major private equity firms, reportedly catapulting its valuation to $10 billion.

A successful monoclonal antibody could undergo scale-up several times across the span of its commercial life, each stage presenting new complexities during sterile fill-finish. As more sponsors turn ...

The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.

PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global supply chain solutions provider, today announced the acquisition of B ...

PCI Pharma Services, a Philadelphia contract drug manufacturer, is investing $50 million into a new manufacturing facility in Rockford that's expected to create about 250 jobs.

Private equity firm Partners Group on Wednesday will announce an agreement to acquire PCI Pharma Services, a Philadelphia-based provider of outsourced services to the global pharmaceutical market ...

The auction of Frazier Healthcare Partners-backed PCI Pharma Services, which potentially valued the pharmaceutical outsourcing company at more than $1 billion, has attracted the interest of ...